International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1296-1302 , 1 August 2010

Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer

Presented at the American Society for Radiation Oncology 51st Annual Meeting, Chicago, IL, November 2, 2009.

  • Jeffrey M. Albert, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Ana M. Gonzalez-Angulo, M.D.

      Affiliations

    • Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Merih Guray, M.D.

      Affiliations

    • Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Aysegul Sahin, M.D.

      Affiliations

    • Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Eric A. Strom, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Welela Tereffe, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Wendy A. Woodward, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Susan L. Tucker, Ph.D.

      Affiliations

    • Department of Biostatistics and Applied Mathematics, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Kelly K. Hunt, M.D.

      Affiliations

    • Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Gabriel N. Hortobagyi, M.D.

      Affiliations

    • Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • ,
  • Thomas A. Buchholz, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX
    • Corresponding Author InformationReprint requests to: Thomas A. Buchholz, M.D., Department of Radiation Oncology, Unit 97, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Tel: (713) 563-2300; Fax: (713) 563-2366

Received 13 October 2009 ,Revised 6 December 2009 ,Accepted 9 December 2009.

References 

  1. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004;6:109–118
  2. Payne SJ, Bowen RL, Jones JL, et al. Predictive markers in breast cancer—The present. Histopathology. 2008;52:82–90
  3. Grann VR, Troxel AB, Zojwalla NJ, et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005;103:2241–2251
  4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  5. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103–112
  6. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894–2904
  7. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005;365:1687–1717
  8. Bedard PL, Piccart-Gebhart MJ. Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer. 2008;8(Suppl. 4):S157–S165
  9. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the Breast Intergroup Trial N9831. J Natl Cancer Inst. 2002;94:855–857
  10. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852–854
  11. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008;21(Suppl. 2):S8–S15
  12. Benson JR, Jatoi I, Keisch M, et al. Early breast cancer. Lancet. 2009;373:1463–1479
  13. National Comprehensive Cancer Network. National Comprehensive Cancer Network clinical practice guidelines in oncology: Breast cancer. 2009; v.1.2009. http://www.nccn.org, accessed Oct 1, 2009.
  14. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–820
  15. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  16. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  17. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC,T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC,TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients [Abstract]. San Antonio Breast Cancer Symposium, 2006.
  18. Rakkhit R, Broglio K, Peintinger F, et al. Significant increased recurrence rates among breast cancer patients with HER2-positive tumors 1 cm or smaller [Abstract]. San Antonio Breast Cancer Symposium, 2008.
  19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:547–581
  20. Cox DR, Oakes N. Analysis of survival data. New York: Chapman and Hall; 1988;
  21. Haffty BG, Brown F, Carter D, et al. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. Int J Radiat Oncol Biol Phys. 1996;35:751–757
  22. Harris EE, Hwang WT, Lee EA, et al. The impact of HER-2 status on local recurrence in women with stage I-II breast cancer treated with breast-conserving therapy. Breast J. 2006;12:431–436
  23. Woodward WA, Strom EA, Tucker SL, et al. Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2003;57:336–344
  24. Fisher B, Dignam J, Tan-Chiu E, et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst. 2001;93:112–120
  25. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–2378
  26. Pietras RJ, Poen JC, Gallardo D, et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 1999;59:1347–1355
  27. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys. 2000;48:1519–1528
  28. Buchholz TA, Huang EH, Berry D, et al. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:1337–1342
  29. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361–1370
  30. Moliterni A, Menard S, Valagussa P, et al. HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol. 2003;21:458–462
  31. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 2003;97:1758–1765

 Conflict of interest: none.

PII: S0360-3016(09)03675-X

doi: 10.1016/j.ijrobp.2009.12.011

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1296-1302 , 1 August 2010

Article Tools

* Image Usage & Resolution